Here are four points:
1. The procedure is used to treat joint injuries, spine pain and degenerative orthopedic conditions, such as osteoarthritis.
2. The patent focuses on the use of an inflammatory agent to prompt repair of cartilage by stem cells.
3. The new patent is key in protecting Regenexx intellectual property on its proprietary stem cell procedure.
4. Regenexx focuses on developing non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions.
More articles on devices:
42 spine, orthopedic devices receive FDA 510(k) clearance in September
Exactech Q3 revenue drops 3%: 10 key notes
Does rhBMP affect pediatric spinal fusion scoliosis patients? 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
